Dr Nick Cammack
Following a first degree in Microbiology at Leeds University, and an MSc in Virology at Reading University, he received an MRC Postgraduate Fellowship to study the differences between vaccine and virulent envelope proteins of Yellow Fever virus at the London School of Hygiene and Tropical Medicine. He was awarded a PhD in 1986.
His intensive training in Virology continued with a Postdoctoral position with Dr.Phil Minor at the National Institute for Biological Standards and Control, before joining Glaxo Group Research in 1989 where he played a key role in the development of Epivir(TM) for the treatment of HIV infection. He joined Roche in February 1997.